DK2091949T3 - Indolderivater som S1P1-receptor agonister - Google Patents

Indolderivater som S1P1-receptor agonister

Info

Publication number: DK2091949T3
Authority: DK; Denmark
Prior art keywords: receptor agonists; indole derivatives; indole; derivatives; agonists
Prior art date: 2006-12-21

Application number

DK07857808.5T

Other languages

English (en)

Inventor

Mahmood Ahmed

James Myatt

David Norton

Dean Andrew Rivers

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-12-21

Filing date

2007-12-19

Publication date

2011-07-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39283563&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2091949(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-12-21 Priority claimed from GB0625647A external-priority patent/GB0625647D0/en

2007-04-19 Priority claimed from GB0707615A external-priority patent/GB0707615D0/en

2007-12-19 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2011-07-18 Application granted granted Critical

2011-07-18 Publication of DK2091949T3 publication Critical patent/DK2091949T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Cardiology (AREA)
Oncology (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Transplantation (AREA)
Hematology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)

DK07857808.5T 2006-12-21 2007-12-19 Indolderivater som S1P1-receptor agonister DK2091949T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0625647A GB0625647D0 (en)	2006-12-21	2006-12-21	Compounds
GB0707615A GB0707615D0 (en)	2007-04-19	2007-04-19	Compounds
PCT/EP2007/064185 WO2008074821A1 (en)	2006-12-21	2007-12-19	Indole derivatives as s1p1 receptor agonists

Publications (1)

Publication Number	Publication Date
DK2091949T3 true DK2091949T3 (da)	2011-07-18

Family

ID=39283563

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK10158582.6T DK2206710T3 (da)	2006-12-21	2007-12-19	Indolderivater som s1p1-receptor agonister
DK07857808.5T DK2091949T3 (da)	2006-12-21	2007-12-19	Indolderivater som S1P1-receptor agonister

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK10158582.6T DK2206710T3 (da)	2006-12-21	2007-12-19	Indolderivater som s1p1-receptor agonister

Country Status (32)

Country	Link
US (1)	US8101775B2 (da)
EP (2)	EP2091949B1 (da)
JP (1)	JP5309034B2 (da)
KR (1)	KR101495927B1 (da)
CN (1)	CN103012390B (da)
AR (1)	AR064452A1 (da)
AT (1)	ATE509927T1 (da)
AU (1)	AU2007336224B2 (da)
BR (1)	BRPI0721127A2 (da)
CA (1)	CA2673468C (da)
CL (1)	CL2007003755A1 (da)
CR (2)	CR10922A (da)
CY (2)	CY1111702T1 (da)
DK (2)	DK2206710T3 (da)
DO (1)	DOP2009000133A (da)
EA (1)	EA017406B1 (da)
ES (1)	ES2389879T3 (da)
HR (2)	HRP20110456T1 (da)
IL (1)	IL199187A (da)
JO (1)	JO2701B1 (da)
MA (1)	MA30999B1 (da)
MX (1)	MX2009006882A (da)
MY (2)	MY148470A (da)
NO (1)	NO20092385L (da)
NZ (1)	NZ577387A (da)
PE (2)	PE20121076A1 (da)
PL (2)	PL2091949T3 (da)
PT (2)	PT2091949E (da)
SG (1)	SG177914A1 (da)
SI (2)	SI2206710T1 (da)
TW (1)	TWI393564B (da)
WO (1)	WO2008074821A1 (da)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2003132B1 (en)	2006-04-03	2014-03-05	Astellas Pharma Inc.	Oxadiazole derivatives as S1P1 agonists
JO2701B1 (en)	2006-12-21	2013-03-03	جلاكسو جروب ليميتد	Vehicles
CA2684385A1 (en) *	2007-04-19	2008-10-30	Glaxo Group Limited	Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (s1p) agonists
GB0807910D0 (en)	2008-04-30	2008-06-04	Glaxo Group Ltd	Compounds
DK2291080T3 (da)	2008-05-14	2015-12-07	Scripps Research Inst	Hidtil ukendte modulatorer af sphingosinphosphatreceptorer
WO2009151621A1 (en) *	2008-06-13	2009-12-17	Arena Pharmaceuticals, Inc.	Substituted (1, 2, 4-0xadiaz0l-3-yl) indolin-1-yl carboxylic acid derivatives useful as s1p1 agonists
WO2009151626A1 (en) *	2008-06-13	2009-12-17	Arena Pharmaceuticals, Inc.	Substituted (1, 2, 4-0xadiaz0l-3-yl) indolin-1-yl carboxylic acid derivatives useful as s1p1 agonists
AR072184A1 (es)	2008-06-20	2010-08-11	Glaxo Group Ltd	Derivados de oxadiazol como agonistas del receptor s1p1
US9149459B2 (en) *	2008-07-23	2015-10-06	Novartis Ag	Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation
CN104311472B9 (zh)	2008-07-23	2020-03-17	艾尼纳制药公司	经取代的1,2,3,4-四氢环戊并[b]吲哚-3-基乙酸衍生物
US8415484B2 (en) *	2008-08-27	2013-04-09	Arena Pharmaceuticals, Inc.	Substituted tricyclic acid derivatives as S1P1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders
US8741923B2 (en) *	2008-12-18	2014-06-03	Merck Serono Sa	Oxadiazole fused heterocyclic derivatives useful for the treatment of multiple sclerosis
EP2202232A1 (en) *	2008-12-26	2010-06-30	Laboratorios Almirall, S.A.	1,2,4-oxadiazole derivatives and their therapeutic use
EP2241558A1 (en) *	2009-04-03	2010-10-20	Merck Serono SA	Oxadiazole derivatives
GB0910689D0 (en) *	2009-06-19	2009-08-05	Glaxo Wellcome Mfg Pte Ltd	Novel compounds
GB0910667D0 (en) *	2009-06-19	2009-08-05	Glaxo Wellcome Mfg Pte Ltd	Novel compounds
WO2011005295A1 (en) *	2009-06-24	2011-01-13	Arena Pharmaceuticals, Inc.	Modulators of the sphingosine-1-phosphate (s1p) receptor useful for the treatment of disorders related thereto
UA107360C2 (en)	2009-08-05	2014-12-25	Biogen Idec Inc	Bicyclic aryl sphingosine 1-phosphate analogs
US8399451B2 (en)	2009-08-07	2013-03-19	Bristol-Myers Squibb Company	Heterocyclic compounds
RS61829B1 (sr)	2009-11-13	2021-06-30	Receptos Llc	Selektivni modulatori receptora sfingozin 1 fosfata i metode hiralne sinteze
WO2011072488A1 (en) *	2009-12-18	2011-06-23	Glaxo Group Limited	Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate 1 (s1p1) receptor agonists
SG10201500639TA (en)	2010-01-27	2015-03-30	Arena Pharm Inc	Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
EP2542554B1 (en) *	2010-03-03	2015-11-04	Arena Pharmaceuticals, Inc.	Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
EP2560969B1 (en)	2010-04-23	2015-08-12	Bristol-Myers Squibb Company	4-(5-isoxazolyl or 5-pyrrazolyl-1,2,4-oxadiazol-3-yl)-mandelic acid amides as sphingosin-1-phosphate 1 receptor agonists
ES2548258T3 (es)	2010-09-24	2015-10-15	Bristol-Myers Squibb Company	Compuestos de oxadiazol sustituidos y su uso como agonistas de S1P1
PT2672823T (pt)	2011-02-07	2016-11-21	Biogen Ma Inc	Agentes que modulam s1p
JP6129159B2 (ja)	2011-05-13	2017-05-17	レセプトスエルエルシー	選択的複素環式スフィンゴシン１−リン酸受容体モジュレーター
EP2567959B1 (en)	2011-09-12	2014-04-16	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
GB201202027D0 (en) *	2012-02-06	2012-03-21	Sareum Ltd	Pharmaceutical compounds
ES2995737T3 (en)	2015-01-06	2025-02-11	Arena Pharm Inc	Compound for use in treating conditions related to the s1p1 receptor
MA42807A (fr)	2015-06-22	2018-07-25	Arena Pharm Inc	Sel l-arginine cristallin d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclo-penta[b]indol-3-yl)acétique (composé 1) pour une utilisation dans des troubles associés au récepteur de s1p1
JP6883882B2 (ja) *	2016-07-22	2021-06-09	シージャーズォアンサガシティニュードラッグデベロップメントカンパニーリミテッド	Ｓ１ｐ１アゴニスト及びその応用
JP7086945B2 (ja)	2016-09-29	2022-06-20	レセプトス・リミテッド・ライアビリティ・カンパニー	狼瘡を処置するための化合物および方法
WO2018151873A1 (en)	2017-02-16	2018-08-23	Arena Pharmaceuticals, Inc.	Compounds and methods for treatment of primary biliary cholangitis
CA3053416A1 (en)	2017-02-16	2018-08-23	Arena Pharmaceuticals, Inc.	Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
EP3801459B1 (en)	2018-06-06	2024-08-07	Arena Pharmaceuticals, Inc.	Methods of treating conditions related to the s1p1 receptor
CN110627778B (zh) *	2018-06-25	2023-01-24	中国科学院上海药物研究所	一类含有1,2,4-噁二唑环的化合物、其制备方法及其在免疫抑制药物中的应用
WO2020051378A1 (en)	2018-09-06	2020-03-12	Arena Pharmaceuticals, Inc.	Compounds useful in the treatment of autoimmune and inflammatory disorders
PH12022551043A1 (en)	2019-10-31	2023-05-03	Idorsia Pharmaceuticals Ltd	Combination of a cxcr7 antagonist with an s1p1 receptor modulator
AU2020397746B2 (en)	2019-12-03	2024-02-01	Lg Chem, Ltd.	Sphingosine-1-phosphate receptor agonist, preparation method therefor, and pharmaceutical composition containing same as active ingredient
BR112022015723A2 (pt) *	2020-02-11	2023-02-14	Syngenta Crop Protection Ag	Compostos de amina cíclica pesticidamente ativos
EP4212156A1 (en)	2022-01-13	2023-07-19	Abivax	Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator
WO2025083549A1 (en)	2023-10-16	2025-04-24	Sun Pharma Advanced Research Company Limited	Methods and combinations of inhibitors of il-23 pathway and modulators of s1p signaling pathway for the treatment of autoimmune disorders

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3939238A1 (de)	1989-11-28	1991-05-29	Bayer Ag	Heterocyclisch substituierte acrylsaeureester
DE4002466A1 (de)	1990-01-28	1991-10-10	Bayer Ag	Substituierte 2-(6-(pyrimidinyl)-indo-l-yl)-acrylsaeureester
US5523312A (en)	1994-09-27	1996-06-04	Sterling Winthrop Inc.	Antipicornaviral agents
DE19620041A1 (de)	1996-05-17	1998-01-29	Merck Patent Gmbh	Adhäsionsrezeptor-Antagonisten
DE19643037A1 (de)	1996-10-18	1998-04-23	Boehringer Ingelheim Kg	Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
JPH1180026A (ja)	1997-09-02	1999-03-23	Yoshitomi Pharmaceut Ind Ltd	新規免疫抑制剤、その使用方法およびその同定方法
AU2003276043A1 (en)	2002-06-17	2003-12-31	Merck & Co., Inc.	1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists
US20060252741A1 (en) *	2003-05-15	2006-11-09	Colandrea Vincent J	3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists
EP1479675A1 (en)	2003-05-19	2004-11-24	Aventis Pharma Deutschland GmbH	Indazole-derivatives as factor Xa inhibitors
CN1859908A (zh) *	2003-10-01	2006-11-08	默克公司	作为s1p受体激动剂的3,5－芳基、杂芳基或环烷基取代的－1,2,4－噁二唑类化合物
CA2547198A1 (en)	2003-12-17	2005-06-30	Merck & Co., Inc.	(3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists
EP1760071A4 (en)	2004-06-23	2008-03-05	Ono Pharmaceutical Co	COMPOUND WITH S1P RECEPTOR BINDING ABILITY AND USE THEREOF
WO2006047195A2 (en)	2004-10-22	2006-05-04	Merck & Co., Inc.	2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists
EP1852420B1 (en)	2005-02-25	2012-10-17	Ono Pharmaceutical Co., Ltd.	Indole compounds for treating respiratory disorders
CN101146529B (zh)	2005-03-23	2012-08-29	埃科特莱茵药品有限公司	新颖噻吩衍生物作为鞘氨醇-1-磷酸酯-1受体激动剂
KR20070121013A (ko)	2005-04-22	2007-12-26	다이이찌 산쿄 가부시키가이샤	헤테로 고리 화합물
EP1893591A1 (en)	2005-06-08	2008-03-05	Novartis AG	POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS
WO2007024922A1 (en)	2005-08-23	2007-03-01	Irm Llc	Immunosuppressant compounds and compositions
GB0601744D0 (en)	2006-01-27	2006-03-08	Novartis Ag	Organic compounds
JP2007262009A (ja)	2006-03-29	2007-10-11	Dai Ichi Seiyaku Co Ltd	ヘテロアリール低級カルボン酸誘導体
EP2003132B1 (en) *	2006-04-03	2014-03-05	Astellas Pharma Inc.	Oxadiazole derivatives as S1P1 agonists
MY149853A (en)	2006-09-07	2013-10-31	Actelion Pharmaceuticals Ltd	Pyridin-4-yl derivatives as immunomodulating agents
JO2701B1 (en)	2006-12-21	2013-03-03	جلاكسو جروب ليميتد	Vehicles
CA2684385A1 (en)	2007-04-19	2008-10-30	Glaxo Group Limited	Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (s1p) agonists

2007
- 2007-12-17 JO JO2007554A patent/JO2701B1/en active
- 2007-12-19 MY MYPI20092612A patent/MY148470A/en unknown
- 2007-12-19 MY MYPI2012004367A patent/MY156822A/en unknown
- 2007-12-19 EA EA200970612A patent/EA017406B1/ru not_active IP Right Cessation
- 2007-12-19 BR BRPI0721127-9A patent/BRPI0721127A2/pt not_active IP Right Cessation
- 2007-12-19 PL PL07857808T patent/PL2091949T3/pl unknown
- 2007-12-19 PL PL10158582T patent/PL2206710T3/pl unknown
- 2007-12-19 HR HR20110456T patent/HRP20110456T1/hr unknown
- 2007-12-19 AR ARP070105729A patent/AR064452A1/es unknown
- 2007-12-19 EP EP07857808A patent/EP2091949B1/en active Active
- 2007-12-19 WO PCT/EP2007/064185 patent/WO2008074821A1/en not_active Ceased
- 2007-12-19 ES ES10158582T patent/ES2389879T3/es active Active
- 2007-12-19 JP JP2009542043A patent/JP5309034B2/ja not_active Expired - Fee Related
- 2007-12-19 EP EP10158582A patent/EP2206710B1/en active Active
- 2007-12-19 PT PT07857808T patent/PT2091949E/pt unknown
- 2007-12-19 AT AT07857808T patent/ATE509927T1/de active
- 2007-12-19 KR KR1020097012841A patent/KR101495927B1/ko not_active Expired - Fee Related
- 2007-12-19 DK DK10158582.6T patent/DK2206710T3/da active
- 2007-12-19 DK DK07857808.5T patent/DK2091949T3/da active
- 2007-12-19 US US12/520,145 patent/US8101775B2/en not_active Expired - Fee Related
- 2007-12-19 SI SI200731001T patent/SI2206710T1/sl unknown
- 2007-12-19 TW TW096148543A patent/TWI393564B/zh not_active IP Right Cessation
- 2007-12-19 CN CN201210396720.5A patent/CN103012390B/zh not_active Expired - Fee Related
- 2007-12-19 SG SG2011095114A patent/SG177914A1/en unknown
- 2007-12-19 NZ NZ577387A patent/NZ577387A/en not_active IP Right Cessation
- 2007-12-19 SI SI200730670T patent/SI2091949T1/sl unknown
- 2007-12-19 PT PT10158582T patent/PT2206710E/pt unknown
- 2007-12-19 AU AU2007336224A patent/AU2007336224B2/en not_active Ceased
- 2007-12-19 CA CA2673468A patent/CA2673468C/en not_active Expired - Fee Related
- 2007-12-19 MX MX2009006882A patent/MX2009006882A/es active IP Right Grant
- 2007-12-20 CL CL200703755A patent/CL2007003755A1/es unknown
2008
- 2008-01-02 PE PE2012000146A patent/PE20121076A1/es not_active Application Discontinuation
- 2008-01-02 PE PE2008000023A patent/PE20081398A1/es not_active Application Discontinuation
2009
- 2009-06-04 IL IL199187A patent/IL199187A/en not_active IP Right Cessation
- 2009-06-05 DO DO2009000133A patent/DOP2009000133A/es unknown
- 2009-06-17 MA MA32003A patent/MA30999B1/fr unknown
- 2009-06-23 NO NO20092385A patent/NO20092385L/no not_active Application Discontinuation
- 2009-07-13 CR CR10922A patent/CR10922A/es unknown
2011
- 2011-07-19 CY CY20111100700T patent/CY1111702T1/el unknown
2012
- 2012-08-29 HR HRP20120685TT patent/HRP20120685T1/hr unknown
- 2012-09-20 CY CY20121100862T patent/CY1113131T1/el unknown
2014
- 2014-07-01 CR CR20140316A patent/CR20140316A/es unknown

Also Published As

Publication number	Publication date
ATE509927T1 (de)	2011-06-15
EA200970612A1 (ru)	2009-10-30
ES2389879T3 (es)	2012-11-02
TWI393564B (zh)	2013-04-21
CY1111702T1 (el)	2015-10-07
CR20140316A (es)	2014-08-20
CA2673468A1 (en)	2008-06-26
EP2206710A1 (en)	2010-07-14
IL199187A (en)	2015-04-30
CL2007003755A1 (es)	2008-08-22
SI2206710T1 (sl)	2012-10-30
JP5309034B2 (ja)	2013-10-09
US20100113796A1 (en)	2010-05-06
NZ577387A (en)	2012-01-12
JP2010513397A (ja)	2010-04-30
HK1130255A1 (en)	2009-12-24
HRP20110456T1 (hr)	2011-07-31
WO2008074821A1 (en)	2008-06-26
MX2009006882A (es)	2009-07-03
CY1113131T1 (el)	2016-04-13
SG177914A1 (en)	2012-02-28
JO2701B1 (en)	2013-03-03
AU2007336224A1 (en)	2008-06-26
KR20090092290A (ko)	2009-08-31
MY156822A (en)	2016-03-31
PL2206710T3 (pl)	2012-11-30
CA2673468C (en)	2015-06-02
IL199187A0 (en)	2010-03-28
MA30999B1 (fr)	2009-12-01
US8101775B2 (en)	2012-01-24
PT2091949E (pt)	2011-07-13
CN103012390B (zh)	2015-08-26
CN103012390A (zh)	2013-04-03
DOP2009000133A (es)	2009-08-15
KR101495927B1 (ko)	2015-02-25
PE20081398A1 (es)	2008-11-19
PE20121076A1 (es)	2012-09-05
EP2091949B1 (en)	2011-05-18
PT2206710E (pt)	2012-09-10
TW200843736A (en)	2008-11-16
BRPI0721127A2 (pt)	2014-03-11
EP2091949A1 (en)	2009-08-26
DK2206710T3 (da)	2012-08-27
EA017406B1 (ru)	2012-12-28
HRP20120685T1 (hr)	2012-09-30
MY148470A (en)	2013-04-30
AU2007336224B2 (en)	2013-01-10
CR10922A (es)	2009-08-12
SI2091949T1 (sl)	2011-08-31
EP2206710B1 (en)	2012-07-04
HK1140761A1 (en)	2010-10-22
PL2091949T3 (pl)	2011-10-31
AR064452A1 (es)	2009-04-01
NO20092385L (no)	2009-08-24

Publication	Publication Date	Title
DK2091949T3 (da)	2011-07-18	Indolderivater som S1P1-receptor agonister
DK2069322T3 (da)	2012-11-05	THIOPHENDERIVATER SOM S1P1/EDG1-receptoragonister
DK2125797T3 (da)	2014-02-10	Aminopyridinderivater som s1p1/edg1-receptoragonister
DK1863474T3 (da)	2009-02-09	Hidtil ukendte thiophenderivater som sphingosin-1-phosphat-1-receptoragonister
DK1856110T3 (da)	2011-08-15	Oxyindol derivater som 5HT4-receptor agonister
DK2029549T3 (da)	2011-02-21	Phenyl-pyrazol-derivater som ikke-steroide glucocoricoid-receptorligander
IL192657A (en)	2015-09-24	Theophenic history as 1edg / 1p1s receptor agonists
DK1989196T3 (da)	2013-04-15	Piperidinoylpyrrolidiner som melanocortin-type 4-receptoragonister
BRPI0715324A2 (pt)	2015-06-23	Composto de indol
DK2094658T3 (da)	2012-02-13	Tetrahydrocyclopenta[B]indolforbindelser som androgenreceptormodulatorer
DK2225231T3 (da)	2011-10-17	Aminotriazolderivater som alx-agonister
DK2195311T3 (da)	2011-05-23	Pyridinderivater som S1P1/EDG1-receptormodulatorer
DK2066669T3 (da)	2011-01-10	Adenosinderivater som A2A-receptoragonister
DK2144897T3 (da)	2011-02-07	8-Oxy-quinolinderivater som bradykinin B2-receptormodulatorer
IL198931A0 (en)	2010-02-17	Benzamide derivatives as ep4 receptor agonists
DK2094709T3 (da)	2010-12-06	Thiazol-pyrazolopyrimidiner som CRF1-receptorantagonister
EP2079466A4 (en)	2011-09-07	SUBSTITUTED INDOLE COMPOUNDS
DK2069310T3 (da)	2012-03-19	Sulfonylpyrazolin-1-carboxamidin-derivater som 5-HT6-antagonister
ATE549350T1 (de)	2012-03-15	Neuropeptid-2-rezeptor-agonisten
DK2049480T3 (da)	2014-01-20	2-arylindolderivater som mPGES-1-hæmmere
DK1904477T3 (da)	2009-03-16	Indol-3-carbonyl-spiro-piperodom-derivater som V1A-receptorantagonister
DK2148873T3 (da)	2012-11-26	4-alkoxypyridazinderivater som hurtigt dissocierende dopamin 2- receptorantagonister
DK2132185T3 (da)	2011-10-03	Pyrimidinyl-piperaziner nyttige som dopamin-D3/D2-receptorligander
DK1740583T3 (da)	2009-10-19	Oxadiazolon-derivater som ppar-delta-agonister
ATE527249T1 (de)	2011-10-15	Indole